Brand Name
ZYNYZ
Generic Name
Retifanlimab-Dlwr
View Brand Information FDA approval date: March 22, 2023
Classification: Programmed Death Receptor-1 Blocking Antibody
Form: Injection
What is ZYNYZ (Retifanlimab-Dlwr)?
ZYNYZ is a programmed death receptor-1 –blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment